Predicting survival in anaplastic astrocytoma patients in a single-center cohort of 108 patients.
Anaplastic astrocytoma
Glioma
Overall survival
Score
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
28
09
2020
accepted:
06
12
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
1
9
2021
Statut:
epublish
Résumé
Current guidelines for the treatment of anaplastic astrocytoma (AA) recommend maximal safe resection followed by radiotherapy and chemotherapy. Despite this multimodal treatment approach, patients have a limited life expectancy. In the present study, we identified variables associated with overall survival (OS) and constructed a model score to predict the OS of patients with AA at the time of their primary diagnosis. We retrospectively evaluated 108 patients with newly diagnosed AA. The patient and tumor characteristics were analyzed for their impact on OS. Variables significantly associated with OS on multivariable analysis were included in our score. The final algorithm was based on the 36-month survival rates corresponding to each characteristic. On univariate analysis, age, Karnofsky performance status, isocitrate dehydrogenase status, and extent of resection were significantly associated with OS. On multivariable analysis all four variables remained significant and were consequently incorporated in the score. The total score ranges from 20 to 33 points. We designated three prognostic groups: A (20-25), B (26-29), and C (30-33 points) with 36-month OS rates of 23%, 71%, and 100%, respectively. The OS rate at 5 years was 8% in group A, 61% in group B and 88% in group C. Our model score predicts the OS of patients newly diagnosed with AA and distinguishes patients with a poor survival prognosis from those with a greater life expectancy. Independent and prospective validation is needed. The upcoming changes of the WHO classification of brain tumors as well as the practice changing results from the CATNON trial will most likely require adaption of the score.
Sections du résumé
BACKGROUND
BACKGROUND
Current guidelines for the treatment of anaplastic astrocytoma (AA) recommend maximal safe resection followed by radiotherapy and chemotherapy. Despite this multimodal treatment approach, patients have a limited life expectancy. In the present study, we identified variables associated with overall survival (OS) and constructed a model score to predict the OS of patients with AA at the time of their primary diagnosis.
METHODS
METHODS
We retrospectively evaluated 108 patients with newly diagnosed AA. The patient and tumor characteristics were analyzed for their impact on OS. Variables significantly associated with OS on multivariable analysis were included in our score. The final algorithm was based on the 36-month survival rates corresponding to each characteristic.
RESULTS
RESULTS
On univariate analysis, age, Karnofsky performance status, isocitrate dehydrogenase status, and extent of resection were significantly associated with OS. On multivariable analysis all four variables remained significant and were consequently incorporated in the score. The total score ranges from 20 to 33 points. We designated three prognostic groups: A (20-25), B (26-29), and C (30-33 points) with 36-month OS rates of 23%, 71%, and 100%, respectively. The OS rate at 5 years was 8% in group A, 61% in group B and 88% in group C.
CONCLUSIONS
CONCLUSIONS
Our model score predicts the OS of patients newly diagnosed with AA and distinguishes patients with a poor survival prognosis from those with a greater life expectancy. Independent and prospective validation is needed. The upcoming changes of the WHO classification of brain tumors as well as the practice changing results from the CATNON trial will most likely require adaption of the score.
Identifiants
pubmed: 33334378
doi: 10.1186/s13014-020-01728-8
pii: 10.1186/s13014-020-01728-8
pmc: PMC7745461
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282Références
Radiat Oncol. 2014 Jun 03;9:128
pubmed: 24893775
Radiat Oncol. 2013 Jul 03;8:161
pubmed: 23822643
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Radiat Oncol. 2018 Dec 29;13(1):257
pubmed: 30594231
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Semin Neurol. 2018 Feb;38(1):19-23
pubmed: 29548048
Acta Oncol. 2013 Jan;52(1):147-52
pubmed: 22686472
Neuro Oncol. 2016 Nov;18(11):1529-1537
pubmed: 27370396
PLoS One. 2017 Jul 5;12(7):e0180457
pubmed: 28678889
Neurooncol Pract. 2019 Sep;6(5):364-374
pubmed: 31555451
Acta Oncol. 2017 Mar;56(3):422-426
pubmed: 28075197
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Lancet. 2017 Oct 7;390(10103):1645-1653
pubmed: 28801186
Cancer Med. 2018 May;7(5):1742-1749
pubmed: 29573214
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Radiother Oncol. 2018 Apr;127(1):121-127
pubmed: 29433917
Radiat Oncol. 2020 May 6;15(1):97
pubmed: 32375830